Autoimmune play Hillstar takes wing with $67M series A: Finance Report

With an approach to treating immune disorders through a targeted reset approach rather than chronic suppression, newly launched Hillstar hopes to put $67 million in series A funding to drive its lead program toward clinical proof of concept.

The Boston-based start-up believes its engineered therapy targeting TRBV9⁺ T cells can enter human testing in 2026, with an initial indication of axial spondyloarthritis. According to CEO Robert Mabry, there is already clinical evidence that targeting TRBV9⁺ T cells can lead to their selective depletion. The mechanism could treat a range of immune diseases without long-term immunosuppression...